CASE REPORTS

 

Synovial sarcoma

 

 

Sucari S.C. Vlok^I; Georg W.W. Wagener^I; Dan Zaharie^II

^IDivision of Radiodiagnosis, Stellenbosch University, South Africa
^IIDepartment of Anatomical Pathology, Stellenbosch University, South Africa

Correspondence

 

 

---

ABSTRACT

Synovial sarcoma is a malignant, predominantly juxta-articular, soft-tissue tumour representing approximately 10% of all soft-tissue sarcomas. Frequently initially incorrectly diagnosed as a benign lesion, it should be considered as a diagnosis when a young adult patient presents with a calcified juxta-articular soft-tissue mass of insidious onset.

---

 

 

Introduction

Synovial sarcoma was first reported in 1893¹ and named after its microscopic resemblance to normal synovium.² It is thought to originate from primitive mesenchymal cells that undergo differentiation to resemble synovial cells.^2,3,4,5

Synovial sarcomas usually occur in adolescents and young adults, with no gender or racial predilection.^2,3,4 They typically affect the extremities (80%-95% of cases),⁴ arising from tendons, tendon sheets and bursal structures. It is important to note that they usually arise beyond the confines of the joint capsule. The single most commonly affected site is the knee.^2,3,4,5,6

Synovial sarcomas are frequently initially incorrectly diagnosed as benign processes such as myositis, synovitis, haematoma, tendinitis or bursitis,² resulting in the time to final diagnosis ranging from two to four years.⁴ It is therefore important to consider synovial sarcoma when a young adult patient presents with a calcified juxta-articular soft-tissue mass of insidious onset.⁵

 

Case report

A 14-year-old boy presented at initial consultation with a one-year history of a tender, slow-growing, juxta-articular left knee mass. Conventional radiographs revealed a soft-tissue mass with coarse calcifications (Figure 1). Magnetic resonance imaging (MRI) displayed a soft-tissue mass with heterogeneous T1 and T2 signal characteristics (Figure 2). An excision biopsy, followed by haematoxylin and eosin staining (Figure 3) and subsequent examinations, was performed in order to establish the diagnosis. The cells were positive for MNF (a pan-epithelial marker), EMA (epithelial membrane antigen), CD99 and bcl2. FISH (fluorescence in situ hybridisation) was positive, confirming the diagnosis of synovial sarcoma.

 

 

Discussion

Synovial sarcoma is a slow-growing, high-grade malignant neoplasm with extensive metastatic potential.^4,5 It accounts for approximately 10% of all soft-tissue sarcomas³ and occurs predominantly in adolescents and young adults between the ages of 15 and 40 years.^2,3,4,5

The extremities are affected in 95% of cases, and the lower limb in 70% of the former.⁶ The neoplasms usually occur in close proximity to large joints of the extremities, predominantly around the knee,^2,3,4,5,6,7 followed by the ankle, elbow and shoulder.² They rarely occur in the head, neck, thorax and abdomen.³

Synovial sarcomas are usually found in close association with tendon sheets, bursae and joint capsules, but joint involvement is rare.² When intra-articular involvement does occur, it usually extends from an extra-articular site into the joint space.^4,5

Patients most commonly present with insidious onset of a peri-articular, palpable, deep-seated swelling or mass that is commonly associated with pain or tenderness.^2,3,4,5,6,7 The duration of symptoms varies from weeks to decades, with an average duration of 2-4 years.^2,3,4

Metastases are present in a quarter of patients at initial diagnosis,⁵ and mainly affect the lungs^2,3,4,5 and, to a lesser extent, lymph nodes, bone and rarely the liver or brain.³

Conventional radiographs may appear normal in approximately 50% of cases.⁴ Typical radiographic features include a juxta-articular soft-tissue mass within 5 cm of the joint and amorphous calcifications in 20%-30% of cases, which are often eccentric or peripheral.⁴ An associated periosteal reaction is present in 15%-20% of cases.^2,3,4,5,6,7

Computed tomography (CT) scanning shows a soft-tissue mass with or without calcifications and bony involvement.^2,3,4,5,6,7 MRI is reserved for local staging of the extent of the disease.

Characteristic changes include a heterogeneous, multi-lobulated soft-tissue mass with a signal intensity similar to or slightly higher than that of muscle on T1W, and a mixed high, intermediate, low signal on T2W that has been described as the triple sign. Fluid-fluid levels are seen in 25% of cases.^2,3,4,5,6

Fluorodeoxyglucose positron emission tomography (FDG-PET) is helpful in differentiating recurrent tumour from post-therapeutic changes, and is valuable in determining prognosis.^3,7

It is important to note that imaging appearances are largely non-specific; biopsy is always necessary for the final diagnosis. At our institution, this is the domain of the clinician and not the radiologist. The current treatment of choice is surgery with or without radiotherapy. The use of chemotherapy is controversial.^3,5

 

Teaching point

Synovial sarcoma features prominently in the differential diagnosis of a soft-tissue tumour around the knee in a young patient.

 

Conclusion

Synovial sarcoma represents approximately 10% of all soft-tissue sarcomas and must be considered in addition to other sarcomas when adolescents or young adults present with insidious onset of a calcified juxta-articular mass, especially around the knee.

 

Acknowledgements

Competing interests

The authors declare that they have no financial or personal relationship(s) that may have inappropriately influenced them in writing this article.

Author contributions

Dr Wagener presented the case at the Musculoskeletal Imaging Congress held in Cape Town in February 2014. The report was written by Dr Vlok and reviewed by Dr Wagener. Histological images and legends were supplied by Dr Zaharie.

 

References

1.Craig RM, Pugh DG, Soule EH. The roentgenologic manifestations of synovial sarcoma. Radiology. 1955;65(6):837. http://dx.doi.org/10.1148/65.6.837        [ Links ]

2.Siegel HJ, Sessions W, Casillas MA, Said-Al-Naief N, Lander PH, Lopez-Ben R. Synovial sarcoma: Clinicopathologic features, treatment and prognosis. Orthopedics. 2007;30(12):1020-1025.         [ Links ]

3.Bakri A, Shinagare AB, Krajewski KM, et al. Synovial sarcoma: Imaging features of common and uncommon primary sites, metastatic patterns and treatment response. AJR. 2012;199(2):W208-W215. http://dx.doi.org/10.2214/AJR.11.8039        [ Links ]

4.Murphey MD, Gibson MS, Jennings BT, Crespo-Rodriguez AM, Fanburg-Smith J, Gajewski DA. Imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics. 2006;26(5):1543-1565.         [ Links ]

5.Roberts CC. STATdx Premier. Synovial sarcoma. Salt Lake City: Amirsys; 2005-2014.         [ Links ] [cited 10-30 May 2014]. Available from: http://my.statdx.com

6.O'Sullivan PJ, Harris AC, Munk PL. Radiological features of synovial cell sarcoma. Br J Radiol. 2008;81(964):346-356. http://dx.doi.org/10.1259/bjr/28335824        [ Links ]

7.Dähnert W. Radiology Review manual. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007; p. 166-167.         [ Links ]

 

 

Correspondence:
Sucari Vlok
11 Bergzicht, Wylant Street
Welgemoed, Bellville 7530
South Africa
Email:sucarivlok@gmail.com

Received: 28 Jul. 2014
Accepted: 13 Nov. 2014
Published: 12 Dec. 2014